Hallvard Holdaas

Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients – a pilot study (2009)

Bremer, Sara, Vethe, Nils T, Rootwelt, Helge, Jørgensen, Pål F, Stenstrøm, Jean, Holdaas, Hallvard, ...

Abstract Background Mycophenolic acid (MPA) is widely used as part of immunosuppressive regimens following allograft transplantation. The large pharmacokinetic (PK) and pharmacodynamic (PD)...

Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study. (2009)

Bremer, Sara, Vethe, Nils T, Rootwelt, Helge, Jørgensen, Pål F, Stenstrøm, Jean, Holdaas, Hallvard, ...

BACKGROUND: Mycophenolic acid (MPA) is widely used as part of immunosuppressive regimens following allograft transplantation. The large pharmacokinetic (PK) and pharmacodynamic (PD) variability and...

Long-term clinical outcome of paediatric kidneys transplanted to adults (2008)

Foss, Aksel, Gunther, Anne, Line, Pål-Dag, Brabrand, Knut, Holdaas, Hallvard, Hartmann, Anders, ...

Background. We have earlier shown an increase in the size and excellent graft function of paediatric kidneys transplanted to adults up to 1 year following transplantation. This study was performed to...

Increased peak systolic velocity in the renal artery of paediatric kidneys transplanted to adult recipients (2008)

Gunther, Anne, Foss, Aksel, Holdaas, Hallvard, Brabrand, Knut, Hartmann, Anders, Line, Paal-Dag, ...

Background. Paediatric kidneys transplanted to adult recipients increase in size after transplantation. It is unknown if the renal artery diameter increases concomitantly with the kidney. This study...

Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients (2008)

Falck, Pål, Vethe, Nils Tore, Åsberg, Anders, Midtvedt, Karsten, Bergan, Stein, Reubsaet, Jan Leo Egge, ...

Background. The calcimimetic drug cinacalcet offers a novel therapeutic option to treat post-transplant hypercalcemia and hyperparathyroidism; however, the interaction with calcineurin inhibitors and...

Renal transplant dysfunction--importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality (2006)

Soveri, Inga, Holdaas, Hallvard, Jardine, Alan, Gimpelewicz, Claudio, Staffler, Beatrix, Fellström, Bengt

Background. Renal transplant recipients (RTR) mainly die of premature cardiovascular disease. Traditional cardiovascular disease risk factors are prevalent in RTR. Additionally, non-traditional risk...

Renal transplant dysfunction--importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality (2006)

Soveri, Inga, Holdaas, Hallvard, Jardine, Alan, Gimpelewicz, Claudio, Staffler, Beatrix, Fellström, Bengt

Background. Renal transplant recipients (RTR) mainly die of premature cardiovascular disease. Traditional cardiovascular disease risk factors are prevalent in RTR. Additionally, non-traditional risk...

Renal transplant dysfunction--importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality (2006)

Soveri, Inga, Holdaas, Hallvard, Jardine, Alan, Gimpelewicz, Claudio, Staffler, Beatrix, Fellström, Bengt

Background. Renal transplant recipients (RTR) mainly die of premature cardiovascular disease. Traditional cardiovascular disease risk factors are prevalent in RTR. Additionally, non-traditional risk...

Renal transplant dysfunction--importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality (2006)

Soveri, Inga, Holdaas, Hallvard, Jardine, Alan, Gimpelewicz, Claudio, Staffler, Beatrix, Fellström, Bengt

Background. Renal transplant recipients (RTR) mainly die of premature cardiovascular disease. Traditional cardiovascular disease risk factors are prevalent in RTR. Additionally, non-traditional risk...

Renal transplant dysfunction--importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality (2006)

Soveri, Inga, Holdaas, Hallvard, Jardine, Alan, Gimpelewicz, Claudio, Staffler, Beatrix, Fellström, Bengt

Background. Renal transplant recipients (RTR) mainly die of premature cardiovascular disease. Traditional cardiovascular disease risk factors are prevalent in RTR. Additionally, non-traditional risk...

Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study (2005)

Fellström, Bengt, Zannad, Faiez, Schmieder, Roland, Holdaas, Hallvard, Jardine, Alan, Rose, Helen, ...

Abstract Background Patients with end-stage renal disease (ESRD) are at high risk of cardiovascular events. Multiple risk factors for atherosclerosis are present in ESRD and may contribute to the...

Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study. (2005)

Fellström, Bengt, Zannad, Faiez, Schmieder, Roland, Holdaas, Hallvard, Jardine, Alan, Rose, Helen, ...

BACKGROUND: Patients with end-stage renal disease (ESRD) are at high risk of cardiovascular events. Multiple risk factors for atherosclerosis are present in ESRD and may contribute to the increased...

Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study. (2005)

Fellström, Bengt, Zannad, Faiez, Schmieder, Roland, Holdaas, Hallvard, Jardine, Alan, Rose, Helen, ...

BACKGROUND: Patients with end-stage renal disease (ESRD) are at high risk of cardiovascular events. Multiple risk factors for atherosclerosis are present in ESRD and may contribute to the increased...

Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study. (2005)

Fellström, Bengt, Zannad, Faiez, Schmieder, Roland, Holdaas, Hallvard, Jardine, Alan, Rose, Helen, ...

BACKGROUND: Patients with end-stage renal disease (ESRD) are at high risk of cardiovascular events. Multiple risk factors for atherosclerosis are present in ESRD and may contribute to the increased...

Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study. (2005)

Fellström, Bengt, Zannad, Faiez, Schmieder, Roland, Holdaas, Hallvard, Jardine, Alan, Rose, Helen, ...

BACKGROUND: Patients with end-stage renal disease (ESRD) are at high risk of cardiovascular events. Multiple risk factors for atherosclerosis are present in ESRD and may contribute to the increased...

Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation (2005)

Holdaas, Hallvard, Fellström, Bengt, Jardine, Alan G., Nyberg, Gudrun, Grönhagen-Riska, Carola, Madsen, Sören, ...

Background. Renal transplant recipients have a significantly reduced life expectancy, largely due to premature cardiovascular disease. The aim of the current analysis was to investigate the...

Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation (2005)

Holdaas, Hallvard, Fellström, Bengt, Jardine, Alan G., Nyberg, Gudrun, Grönhagen-Riska, Carola, Madsen, Sören, ...

Background. Renal transplant recipients have a significantly reduced life expectancy, largely due to premature cardiovascular disease. The aim of the current analysis was to investigate the...

Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation (2005)

Holdaas, Hallvard, Fellström, Bengt, Jardine, Alan G., Nyberg, Gudrun, Grönhagen-Riska, Carola, Madsen, Sören, ...

Background. Renal transplant recipients have a significantly reduced life expectancy, largely due to premature cardiovascular disease. The aim of the current analysis was to investigate the...

Atorvastatin improves endothelial function in renal-transplant recipients (2001)

Åsberg, Anders, Hartmann, Anders, Fjeldså, Ellen, Holdaas, Hallvard

Background. Hyperlipidaemia and endothelial dysfunction are common features in cyclosporin A (CsA)‐treated renal transplant recipients. Endothelial dysfunction may contribute to...